{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T11:39:27Z","timestamp":1777894767225,"version":"3.51.4"},"reference-count":18,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.clgc.2018.09.013","type":"journal-article","created":{"date-parts":[[2018,9,24]],"date-time":"2018-09-24T12:57:33Z","timestamp":1537793853000},"page":"e92-e96","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Itraconazole as a Noncastrating Treatment for Biochemically Recurrent Prostate Cancer: A Phase 2 Study"],"prefix":"10.1016","volume":"17","author":[{"given":"Mina","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haemin","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terence W.","family":"Friedlander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence","family":"Fong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy M.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric J.","family":"Small","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao X.","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tammy J.","family":"Rodvelt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigid","family":"Miralda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Stocksdale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles J.","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rahul","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2018.09.013_bib1","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2005.02.111","article-title":"Outcome predictors for the increasing PSA state after definitive external-beam radiotherapy for prostate cancer","volume":"23","author":"Zelefsky","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2018.09.013_bib2","first-page":"S42","article-title":"Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy","volume":"172","author":"D\u2019Amico","year":"2005","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2018.09.013_bib3","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1201546","article-title":"A\u00a0phase III randomized trial of intermittent versus continuous androgen suppression for PSA progression after radical therapy (NCIC CTG PR.7\/SWOG JPR.7\/CTSU JPR.7\/UK Intercontinental Trial CRUKE\/01\/013)","volume":"367","author":"Crook","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2018.09.013_bib4","first-page":"240","article-title":"Intermittent androgen deprivation: update of cycling characteristics in patients without clinically apparent metastatic prostate cancer","volume":"58","author":"Grossfeld","year":"2001","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2018.09.013_bib5","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S1470-2045(16)00107-8","article-title":"Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial","volume":"17","author":"Duchesne","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2018.09.013_bib6","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1200\/JCO.2006.05.9741","article-title":"Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy","volume":"24","author":"Braga-Basaria","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2018.09.013_bib7","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/cncr.21642","article-title":"Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen deprivation therapy","volume":"106","author":"Basaria","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2018.09.013_bib8","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1042\/cs1040195","article-title":"Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia","volume":"104","author":"Dockery","year":"2003","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.clgc.2018.09.013_bib9","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1210\/jcem.86.9.7851","article-title":"The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer","volume":"86","author":"Smith","year":"2001","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.clgc.2018.09.013_bib10","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1210\/jcem.87.2.8299","article-title":"Changes in body composition during androgen deprivation therapy for prostate cancer","volume":"87","author":"Smith","year":"2002","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.clgc.2018.09.013_bib11","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1210\/jc.2005-2507","article-title":"Insulin sensitivity during combined androgen blockade for prostate cancer","volume":"91","author":"Smith","year":"2006","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.clgc.2018.09.013_bib12","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1200\/JCO.2006.06.2497","article-title":"Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer","volume":"24","author":"Keating","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2018.09.013_bib13","doi-asserted-by":"crossref","first-page":"6764","DOI":"10.1158\/0008-5472.CAN-11-0691","article-title":"Itraconazole inhibits angiogenesis and tumor growth in non-small cell lung cancer","volume":"71","author":"Aftab","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.clgc.2018.09.013_bib14","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.ccr.2010.02.027","article-title":"Itraconazole, a commonly used antifungal that\u00a0inhibits Hedgehog pathway activity and cancer growth","volume":"17","author":"Kim","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clgc.2018.09.013_bib15","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1634\/theoncologist.2012-314","article-title":"Repurposing itraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase 2 trial in men with metastatic castration-resistant prostate cancer","volume":"18","author":"Antonarakis","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.clgc.2018.09.013_bib16","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/pcan.2014.27","article-title":"Inhibition of the androgen receptor by mineralocorticoids at levels physiologically achieved in serum in patients treated with abiraterone acetate","volume":"17","author":"Kim","year":"2014","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.clgc.2018.09.013_bib17","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial","volume":"36","author":"Ost","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2018.09.013_bib18","first-page":"639","article-title":"DNA vaccine encoding prostatic acid phosphatase elicits long-term T-cell responses in patients with recurrent prostate cancer","volume":"33","author":"Becker","year":"2010","journal-title":"J\u00a0Immunother"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767318306293?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767318306293?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:32:05Z","timestamp":1761564725000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767318306293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S1558767318306293"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2018.09.013","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Itraconazole as a Noncastrating Treatment for Biochemically Recurrent Prostate Cancer: A Phase 2 Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2018.09.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}